to assess the efficacy of acitretin in acquired dermatoses with dermal hyperpigmentatio
Not Applicable
- Conditions
- Health Condition 1: null- acquired dermal macular hyperpigmentation/ Lichen planus pigmentosus
- Registration Number
- CTRI/2018/06/014588
- Lead Sponsor
- ot applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients with a cliniopathological diagnosis of ADMH (acquired dermal macular hyperpigmentation)
2. Age >18 years
Exclusion Criteria
1. Age < 18 years.
2. Pregnancy/Lactation
3. Child bearing age females with incomplete family status
4. Patients refusing practice of contraceptive measures
5. Patients with severe hepatic, renal disease or dyslipidemia
6. Pre existing malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does acitretin modulate in acquired dermal macular hyperpigmentation and lichen planus pigmentosus?
How does acitretin compare to isotretinoin or hydroquinone in treating lichen planus pigmentosus efficacy and recurrence rates?
What are the primary clinical endpoints in the CTRI/2018/06/014588 acitretin pilot study for acquired dermal macular hyperpigmentation?
Which biomarkers predict response to acitretin in acquired dermal macular hyperpigmentation patients with RARβ expression variability?
Are there synergistic effects of acitretin with other retinoids or depigmenting agents in treating lichen planus pigmentosus?